1,550 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Ratan Capital Management LP

Ratan Capital Management LP bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,550 shares of the medical research company’s stock, valued at approximately $777,000.

Other institutional investors also recently modified their holdings of the company. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $1,212,000. Rakuten Investment Management Inc. bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $30,810,000. Glenview Trust Co acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $12,696,000. North Star Asset Management Inc. bought a new position in Thermo Fisher Scientific in the second quarter valued at $30,456,000. Finally, Empowered Funds LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $18,247,000. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $621.87 on Friday. The company has a market capitalization of $229.94 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 2.57 and a beta of 0.85. The stock’s 50 day moving average is $558.64 and its 200-day moving average is $512.08. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. Wolfe Research initiated coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Royal Bank Of Canada boosted their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, Piper Sandler increased their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.